Patients receive heart transplants as a life-saving measure after heart failure; thus, ensuring the success of the transplant is of utmost importance. Rejection is a primary cause for heart transplant failure, and consequently, patients must take drugs that suppress the immune system to prevent rejection. However, these drugs are highly unspecific and cause serious side effects that can be life-threatening. New immunosuppressive drugs that can prevent transplant rejection while allowing normal immune function can greatly improve care and patient outcomes.
COVID-19 is the largest pandemic of the 21st century, affecting over 6.6 million individuals and claiming over 391,000 lives worldwide as of June 4, 2020. It is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), which uses a receptor to gain entry into the host and cause active infection. This project involves the expertise of PROOF Centre and Professors Don Sin and Pascal Bernatchez.
Many babies die within the first month of life from infectious diseases. Despite successful neonatal vaccination programs, it is not yet possible to accurately predict if a vaccine will work on a newborn child, at the individual “personalized” level. We need to better understand the mechanism of antibody generation after vaccination to improve immunization programs. This project will work in that direction by analyzing novel data obtained from neonates in The Gambia and then validate the findings with data from Papua New Guinea (PNG).
Join a thriving innovation ecosystem. Subscribe now